Navigation Links
Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development

ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has created a new proprietary process to develop a vaccine candidate against Severe Acute Respiratory Syndrome (SARS). The company also received renewed research funding from the National Institutes of Health (NIH) to continue preclinical development of SARS vaccine candidates using Novavax's virus-like particle (VLP) technology.

"Until now, it has been difficult to produce VLP vaccine candidates against SARS and other complex infectious disease targets because many of these biological structures do not assemble efficiently," said Dr. Gale Smith, Vice President, Vaccine Development. "Our new proprietary process uses select components of SARS and other structural proteins that combine with cell membranes to form distinctive SARS coronavirus nanoparticles, which are nearly identical to the human SARS virus but lack the genetic material needed to replicate and cause disease."

"This new approach to create VLPs will allow us to continue our work to develop a SARS vaccine candidate and expand the potential applications of our vaccine technology to a broad range of infectious diseases around the world," said Rahul Singhvi, President and Chief Executive Officer of Novavax, Inc.

Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus and was first reported in Asia in February 2003. According to the World Health Organization (WHO), subsequent to the 2003 breakout, over 8,000 people were infected, with 774 reported deaths. While there is currently no known reported SARS transmission globally, WHO and other such agencies continue to monitor the SARS situation on a global basis as health officials remain concerned that SARS or similar disease could reemerge.

The SARS VLP program is conducted under an NIH grant. Novavax does not have the commercial rights to this product candidate.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing a new, efficient manufacturing solution. Additional information about Novavax is available at and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; the Company may not have the personnel or capital resources to expand its product candidate pipeline; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
2. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
3. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
4. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
5. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
6. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
7. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
8. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
9. BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials
10. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
11. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
Post Your Comments:
(Date:12/1/2015)... --> --> ... by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic ... Analysis - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 40,281.6 Million in 2015, at ... Browse 37 market data T ...
(Date:12/1/2015)... Pharma Tech Outlook recently conducted a comprehensive ... Management Solution Providers - 2015 .  After careful consideration ... CIOs, VCs, analysts, and the Pharma Tech Outlook editorial ... 10 clinical data management solution providers (check out the ... 36 respectively). --> ...
(Date:12/1/2015)... Ohio , Dec. 1, 2015 ... to its GeneSight® Psychotropic test giving healthcare providers an ... medication decisions for patients suffering from depression, anxiety, ... other behavioral health conditions. i ... --> With the addition of two ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per ... decreases in utilization of hospital and nonhospital care, according to a recent study by ... for Louisiana, 16th Edition , found medical payments per claim with more than seven ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first ... Annual Meeting from November 29 to December 4, 2015. , MED-TAB is ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare ... management and population health arenas, is pleased to announce that VIP Care Services, ... has successfully implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic ...
Breaking Medicine News(10 mins):